Skip to main navigation Skip to search Skip to main content

Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity

  • Daniel H. Sterman
  • , Rainer Wiewrodt
  • , Michael Kiefer
  • , Steven M. Albelda
  • , Makoto Odaka
  • , Kunjlata M. Amin
  • , Larry R. Kaiser
  • , Yi Zhang
  • , Guan Ping Gao
  • , James M. Wilson
  • , James Barsoum
  • University of Pennsylvania
  • Biogen IDEC

Research output: Contribution to journal › Article › peer-review

111 Scopus citations

Abstract

Malignant mesothelioma remains an incurable disease for which immune-modulatory therapies, such as exogenous cytokines, have shown some promise. One such cytokine, IFN-β, has potent anti-proliferative and immunostimulatory activity in vitro, but its in vivo use has been limited by toxicity. We thus conducted studies evaluating intracavitary delivery of a replication-deficient adenoviral (Ad) vector encoding for the murine IFN-β gene (Ad.muIFN-β) in mouse models of malignant mesothelioma. In contrast to multiple injections of recombinant protein, a single i.p. injection of Ad.muIFN-β into animals with established tumors elicited remarkable antitumor activity leading to long-term survival in >90% of animals bearing either AB12 or AC29 i.p. mesotheliomas. A control adenovirus vector had minimal antitumor effect in vivo. Significant therapeutic effects were also seen in animals treated with large tumor burdens. Importantly, treatment of i.p. tumor also led to reduction of growth in tumors established at a distant site (flank). A number of experiments suggested that these effects were attributable to an acquired CD8+ T-cell-mediated response including: (a) the induction of long-lasting antitumor immunity; (b) loss of efficacy of Ad.muIFN-β in tumor-bearing, immune-deficient (SCID, SCID/beige) mice; (c) detection of high levels of specific antitumor cytolytic activity from unstimulated splenocytes harvested from Ad.muIFN-β-treated animals that was abolished by CD8+ T-cell depletion; and (d) abrogation of antitumor effects of Ad.muIFN-β in tumor-bearing CD8+ T-cell-depleted animals. These data show that intracavitary IFN-β gene therapy using an adenoviral vector provides strong CD8+ T-cell-mediated antitumor effects in murine models of mesothelioma and suggest that this may be a promising strategy for the treatment of localized tumors such as mesothelioma or ovarian cancer in humans.

Original languageEnglish
Pages (from-to)6201-6212
Number of pages12
JournalCancer Research
Volume61
Issue number16
StatePublished - 15 Aug 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity'. Together they form a unique fingerprint.

Cite this